P aravalvular leaks (PVLs) have been a recognized problem after surgical valve replacement since prosthetic valves were first implanted for aortic and mitral valve disease 5 decades ago. 1 Although the reported incidence varies considerably, it is generally estimated that a PVL of some magnitude is present in ≈7% to 17% of mitral and 2% to 10% of aortic valve replacement prostheses. [2] [3] [4] [5] Most PVLs are small and inconsequential, but anywhere from 1% to 5% of aortic or mitral valve replacement procedures are complicated by a clinically relevant PVL. [2] [3] [4] [5] Although the use of transcatheter devices to close prosthetic PVLs was described >20 years ago, 6 this procedure remained relatively rare until recently, but with the availability of nitinol mesh devices designed for occlusion of various other communications, transcatheter PVL closure has become a regular, although still somewhat uncommon, procedure for many structural interventional cardiologists. 4, 5, [7] [8] [9] [10] [11] [12] Moreover, as transcatheter aortic valve replacement has become increasingly widespread, and paravalvar regurgitation has been recognized as one of its most frequent and significant complications, 13 an entirely new domain has opened up, namely, management of PVLs after transcatheter aortic valve replacement.
Literature on PVL device closure comprises a handful a modest-sized, single-center series and many more single or small case reports. 4, 5, 7, [14] [15] [16] [17] [18] [19] [20] Based on these series, device closure is technically unsuccessful in 5% to 35% of cases, for various reasons, including inability to cross the defect with a wire or delivery catheter, dislodgement/embolization of the device, incomplete closure of the defect, or interference by the device with the prosthetic valve. Even if the device is delivered, remains in place, and reduces flow, the treatment may be clinically inadequate, sometimes because of persistent or new hemolysis, and sometimes for reasons that are less clear. Considering both technical and clinical outcomes, published series have reported success in anywhere from 55% to 77% of patients who undergo closure. Among those in whom these measures of success are met, PVL may not be completely occluded, and the potential for later complications or failure remains. For patients who undergo technically and clinically successful transcatheter PVL closure, the benefits compared with medical or surgical treatment can be profound. Unfortunately, as the limited literature demonstrates, there are still too many patients for whom there is no or very modest benefit. We should be able to do better.
Despite the growing prevalence of PVLs and catheter-based interventions to close them, there are no devices that were designed, tested, or approved for PVL closure. Thus, transcatheter PVL closure is invariably performed with devices that were specified and approved for other purposes. Although closure has been performed with embolization coils and double-umbrella devices, 6,21 most series have used primarily Amplatzer occluders (St Jude Medical, Minneapolis, MN), including devices approved in the United States or elsewhere for closure of patent ductus arteriosus, ventricular septal defects, atrial septal defects, or nonspecific vessels or vascular anomalies. 4, 5, 7, [15] [16] [17] [18] Although all of these devices may be suitable and sufficient in some, or even many, cases, when it comes to PVL closure, they clearly have limitations related to size, shape, closure characteristics, and delivery system features. According to some investigators, one of the best fitting devices for PVL closure is the Amplatzer Vascular Plug III, which is oblong rather than circular in cross-section, is relatively short and low profile, and has extended rims. 22, 23 These features and the recent popularity of this device for PVL closure outside the United States notwithstanding, it was neither designed nor approved for this indication. The Amplatzer Vascular Plug III received a CE Mark in Europe in May 2008 for vascular occlusion, and although its manufacturer at the time (AGA Inc) applied for 510(k) clearance in the United States that same year, it was not approved, and there has been no subsequent regulatory submission or approval for the device. All the same, several recent reports from outside the United States have highlighted the use of the Amplatzer Vascular Plug III for PVL closure, although on first glance the outcomes do not seem to differ markedly from various other devices that have been used.
Reviewing the literature on transcatheter PVL closure, especially the many case reports and small series, one is struck by a recurring theme: the inadequacy of current devices and the need for purpose-specific PVL occluders. In particular, this conclusion is advanced in reports that focus on unsuccessful attempts at or complications of PVL closure, both of which are frequently attributed to inappropriate devices. It is safe to say that this proposition is accurate. Available devices used off-label to close PVLs fall short in many respects. Depending on the location of the defect relative to the prosthesis, devices implanted to close a PVL often protrude in one direction or another, sometimes unpredictably as they conform to the constraints of the PVL, and may interfere with mechanical valve leaflets or coronary arteries, for example. Such complications are not all that common, but there is almost inevitably a square-peg-in-a-round-hole dilemma, even when multiple devices are placed adjacent one another, as the circular/ cylindrical devices may not close the crescent-shaped or serpiginous defect completely, which can leave the patient with persistent congestive symptoms if the residual leak is large or ongoing/new problems related to hemolysis even if the leak is small. One means of improving the outcomes of PVL closure could be the availability of a device or devices designed specifically for this purpose, devices that fit the defect more precisely and reliably, and that both close the PVL effectively and are less likely to interfere with prosthetic valve leaflets or other important structures. Whether development of anatomically appropriate and effective devices is practically feasible, there is some hope. For instance, a recent report from Turkey described the treatment of 2 patients with a novel PVL-specific occlusion device that is fabricated in 2 different shapes and multiple sizes and is similar in composition to Amplatzer occluders. 24 Given all of this, why is there no PVL closure device on track for investigation and commercialization in the United States? Undoubtedly, a variety of factors are at play. The bottom line, of course, is the bottom line-financial incentives and disincentives to embarking on such an effort do not add up. The cost of bringing class III devices to market under the current US regulatory system is enormous, and the payoff, whether direct or ancillary, understandably must be there to make it a commercially viable proposition for most companies. But a PVL device is far from a sure thing. Anatomically, PVLs are complicated and variable and, overall, not thoroughly characterized. Thus, generally speaking, PVLs may not be amenable to treatment with a single device design, which increases the complexity and cost of development, testing, and navigation of the regulatory system. In addition, the limited understanding of 3-dimensional and dynamic anatomy may make it difficult to prioritize and optimize device design features. Although PVLs are increasingly recognized and managed in catheterization laboratory, defects that merit closure remain a small-volume market relative to other high-impact structural interventional devices. Also, the high-yield segment of the market is not clear. Patients can be incredibly complex, and both effectiveness of treatment and assignment of a clear treatment effect may not be straightforward. In addition, the risks and outcomes of alternative treatments are not well defined, so it may be difficult to pinpoint particular opportunities within the broad PVL landscape for which there is a strongly favorable product risk/benefit ratio, that is, for filling a sizable unmet need with a high likelihood of success. Compounding the complexity of the scenario is the fact that clinical outcomes of reported studies are often good but not necessarily great, and complications are somewhat common-when transcatheter PVL closure is effective, the impact can be dramatic, but patients are often complex and it is plausible that the effect size needed to demonstrate efficacy would be impractical.
Clearly, this is an important but confounding issue. But it is just one of many examples of the broader problem. Likewise, the concerns underlying this editorial are broader in scope than simply PVL closure or the prospect of an approved device for this purpose. The issue at hand is development and approval of devices for relatively uncommon or anatomically challenging lesions for which there is a clear need, be they cardiac or noncardiac conditions, congenital or acquired diseases, or pediatric or adult patients. At risk of sounding naive, I cannot help but ask whether the market can and should prevail, and if/when we will find another way. In some respects, lessons may be gleaned from experience with devices intended for congenital cardiac applications, of which there are very few.
As I discussed in a previous editorial, structurally and philosophically, the US Food and Drug Administration (FDA) seems to appreciate the dilemma of facilitating more efficient and economically feasible mechanisms for providing safe and effective medical devices to serve pediatric and congenital disease populations, and is making efforts to improve the process even further. 25 For example, the Office of Orphan Products Development and the Office of Pediatric Therapeutics are 2 of 4 FDA programs that operate under the auspices of the Office of Special Medical Programs. There are funding mechanisms administered through the Office of Orphan Products Development that, albeit limited in scope, aim to advance the prospects of approval or extended indications for devices to treat rare diseases. The FDA's Humanitarian Use Device (HUD) program, established in 1990, was designed to provide an alternative, less demanding approval pathway for medical devices intended to be used in <4000 patients in the United States annually. Most pediatric indications fall into this volume stratum. Although the burden of proof of effectiveness is lower for HUD devices, once a device is granted an Humanitarian Device Exemption (HDE) approval, it exists in a vast grey area in the regulatory landscape, which has implications for coverage by payers, oversight of clinical usage by institutional review boards, and prospective research. The lower bar for approval may facilitate feasible and relatively cost-effective clinical trials, but the end result may be a more burdensome process for clinical application. HUD and HDE are not comprehensive solutions, but they are a foundation.
The problem of developing and commercializing interventional devices, particularly class III devices, for pediatric, congenital, or other small-to-borderline size markets in the United States is significant and unresolved. [26] [27] [28] Legislative mandates aside, there are numerous impediments and few willing adventurers, which is understandable but vexing, nonetheless. In order for the system to work, as stressed and important as it is, all of the stakeholders-patients, physicians, professional groups, the FDA, inventors, and device manufacturers-must work together to advance the various relevant and sometimes competing agendas. Physicians may be in the best position to understand and articulate the need for devices or tools and can initiate Investigational Device Exemption trials of novel applications for approved devices, but regardless of the outcomes of such studies, except perhaps in unique circumstances, they cannot independently seek regulatory approval for a new or
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February 2014 extended indication. Although less burdensome pathways to approval, such as the HDE mechanism, arguably lend themselves to more expeditious commercialization of relatively small market or otherwise commercially marginal devices, a broader array of opportunities and facilities to address these orphan niches is necessary. Examples of 2 promising but still limited mechanisms for working alongside the prevailing market forces are illustrated below. Coordination by funding and regulatory agencies to facilitate the efficient development of pediatric-focused device technology is an obvious but uncommon scenario. In 2004, the National Heart, Lung, and Blood Institute (NHLBI) Pediatric Circulatory Support Program (PCSP) was launched, providing a coordinated effort to foster preclinical development of circulatory support devices specifically for pediatric population. 29 Four years later, the NHLBI issued a request for proposals for the Pumps for Kids, Infants, and Neonates (PumpKIN) program as the logical next step in this agenda, namely, to support and facilitate the progress of pediatric circulatory device programs toward an investigational device exemption trial. 29 The application process was coordinated with submission of pre-Investigational Device Exemption applications to the FDA. Because the PumpKIN trial is only now getting underway, the final product remains to be seen. Even so, it must be recognized, thus far, as a successful experiment in coordinated funding and regulatory support in the service of addressing an important but relatively small-market medical need. Further efforts along these lines may be an important means of facilitating the development of otherwise commercially risky device technologies.
Another potentially creative approach to this problem is facilitation by the nonprofit sector. For example, PediaWorks is a nonprofit organization founded with a mission of developing "pediatric-specific devices based on clinical need rather than financial return," with extensive physician input toward prioritizing the needs and goals (http://www.pediaworks.org). In 2010, PediaWorks partnered with the Japanese medical device manufacturer Medikit Co, Ltd, to form PediaVascular, Inc (Cleveland, OH), "a social venture to help alleviate the shortage of medical devices for use in pediatric patients" (http:// www.pediavascular.com). Two years later, PediaVascular secured 510(k) clearance for Super Sheath introducer sheaths and Mongoose angiography catheters-the first introducer sheaths and angiography catheters, respectively, to receive pediatric indications for use from the FDA. Obviously, 510(k) approval for catheters is a modest undertaking compared with bringing a class III medical device to market, but it is a positive first step and an indication that nonprofit-driven processes and partnering may be a viable strategy in this rarefied arena.
Whether such programs as these are appropriate for PVL devices or other nonpediatric but relatively small-market interventional technologies remains to be seen. Regardless, these approaches highlight the potential role for alternative strategies in the present environment. In focusing on deficiencies in the system, I do not mean to overlook the dedication and contributions of medical device manufacturers with bona fide track records in developing products specifically for pediatrics or other small markets. While essential, however, they are not yet sufficient. Thus, if established market forces do not adequately serve these marginal markets, additional attention must be directed toward not only changing and improving the current system but also working in parallel through alternative channels.
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